530 related articles for article (PubMed ID: 17882949)
1. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
2. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
3. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
4. HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency.
Paulussen AD; Raes A; Jongbloed RJ; Gilissen RA; Wilde AA; Snyders DJ; Smeets HJ; Aerssens J
Cardiovasc Res; 2005 Aug; 67(3):467-75. PubMed ID: 15958262
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
7. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.
Perrin MJ; Subbiah RN; Vandenberg JI; Hill AP
Prog Biophys Mol Biol; 2008; 98(2-3):137-48. PubMed ID: 19027781
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
9. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
[TBL] [Abstract][Full Text] [Related]
10. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Sanguinetti MC; Mitcheson JS
Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
12. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
13. hERG potassium channels and cardiac arrhythmia.
Sanguinetti MC; Tristani-Firouzi M
Nature; 2006 Mar; 440(7083):463-9. PubMed ID: 16554806
[TBL] [Abstract][Full Text] [Related]
14. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
Hancox JC; James AF
Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
[TBL] [Abstract][Full Text] [Related]
15. Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6.
Lu Y; Mahaut-Smith MP; Huang CL; Vandenberg JI
J Physiol; 2003 Aug; 551(Pt 1):253-62. PubMed ID: 12923204
[TBL] [Abstract][Full Text] [Related]
16. Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine.
Kim MD; Eun SY; Jo SH
Eur J Pharmacol; 2006 Aug; 544(1-3):82-90. PubMed ID: 16860311
[TBL] [Abstract][Full Text] [Related]
17. Modulation of HERG potassium channel function by drug action.
Thomas D; Karle CA; Kiehn J
Ann Med; 2004; 36 Suppl 1():41-6. PubMed ID: 15176423
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of cardiac potassium channels.
Tamargo J; Caballero R; Gómez R; Valenzuela C; Delpón E
Cardiovasc Res; 2004 Apr; 62(1):9-33. PubMed ID: 15023549
[TBL] [Abstract][Full Text] [Related]
19. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
20. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
